13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
88,020 |
29.05.24 17:35:36 |
-0,580 |
-0,65% |
0,000 |
0,000 |
88,450 |
88,600 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
963,240 |
29.05.24 21:14:03 |
-9,920 |
-1,02% |
962,900 |
963,840 |
970,000 |
973,160 |